Site Search     
The Clinical Cardiovascular Research Center

 
Cara East, M.D.
Attending Cardiologist, North Texas Heart Center, Baylor University Medical Center
Director, Clinical Cardiovascular Research Center, Baylor University Medical Center
Clinical Director, Noninvasive Laboratory, Jack and Jane Hamilton Heart and Vascular Hospital, Baylor University Medical Center
 
Education: 1973 Lubbock-Cooper High School, Lubbock, Texas
1977 B.A. Biology, Rice University, Houston, Texas
1981 M.D., The University of Texas SW Med School, Dallas, Texas
Training: 1981-82 Internship Int Med, Parkland Memorial Hospital, Dallas, Texas
1982-84 Residency Int Med, Parkland Memorial Hospital, Dallas, Texas
1984-87 Fellowship Endocrin and Metab, UTSW, Dallas, Texas
1988-90 Fellowship CV Disease, Baylor Univ Med Center, Dallas, Texas
Board Certifications:
  American Board of Internal Medicine
Endocrinology & Metabolism
Cardiovascular Disease
National Board of Echocardiography
Professional Societies:
American College of Physicians
American Society of Echocardiography
American Heart Association, Professional Member
Dallas County Medical Society
Texas Medical Association
American Medical Association
 
Research appointments:
Cholesterol and Recurrent Events (CARE) Research Study
  Executive Committee, Dr. Eugene Braunwald, chair 1991 to 1996 Endpoints Committee, Dr. Marc Pfeffer, chair 1991 to 1996 Ancillary Studies Committee, Dr. Frank Sacks 1992 to 1993
 
Principal investigator, Clinical Cardiovascular Research Center, Baylor:
1. A study of outcomes of young women with acute myocardial infarction. Yale Univ School of Medicine, NIH grant pending, 2005.
2. SAMe: The effect of oral S-adenosylmethionine (SAMe) on blood levels of homocysteine in human subjects. NIH grant pending, 2005.
3. Validd: A multi-center, randomized, placebo controlled, double-blind study to evaluate the effect of the angiotensin II antagonist valsartan on diastolic dysfunction in patients with hypertension and diastolic dysfunction. 2005 to present, Novartis.
4. Torcetrapib: Phase 3 evaluation of the fixed combination torcetrapib/atorvastatin compared with atorvastatin alone on the occurrence of major cardiovascular events in subjects with coronary heart disease or risk equivalents. 2004 to present, Pfizer.
5. HOLT: Open-label, pilot study of homocysteine-lowering therapies in patients with chronic renal insufficiency. 2004-present, Cardiovascular Research Committee, Baylor University Medical Center.
6. Accomplish: Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension. 2004-present, Novartis.
7. ARISE: Aggressive reduction of inflammation stops events reduction of vascular inflammation and coronary atherosclerosis with a V-protectant. 2004-present, Atherogenics.
8. GUARD: A multicenter, double-blind, randomized, parallel group study to evaluate the effects of Lotrel® and Lotensin Hct® on microalbuminuria in mild to moderate hypertensive subjects with type 2 diabetes mellitus. 2003-present, Novartis.
9. ICPOP: The effect of niacin ER/Lovastatin on peak walking time in patients with intermittent claudication. 2003-present, Kos.
10. ON TARGET/Transcend: (On-going telmisartan alone and in combination with ramipril global endpoint trial) and including a parallel study TRANSCEND (telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease). 2002-present, Boehringer-Ingelheim.
11. PROVE IT: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. 2000-2003, Bristol-Myers Squibb.
12. CHESS: A multicenter, double-blind, randomized, parallel, 28-week study to evaluate the efficacy and safety of simvastatin 80 mg/day in patients with hypercholesterolemia: Comparative HDL efficacy and safety study. 2000-2002, Merck.
13. ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack. 1995-2003, National Institutes of Health.
14. Cholestanol: Association of high serum cholestanol levels with Achilles tendon xanthomas in patients with heterozygous familial hypercholesterolemia. 2000, Wayne Foundation.
15. OVERTURE: Omapatrilat versus enalapril randomized trial of utility in reducing events. 2000, Bristol-Myers Squibb.
16. Pravastatin: Double blind comparison of 10, 20, 40, and 80 mg doses of a modified-release formulation of pravastatin, of atorvastatin 10 mg, and/or simvastatin 20 mg with placebo in hypercholesterolemic subjects. 1999, Bristol-Myers Squibb.
17. TNT (Treating to new Targets): The effect of LDL-cholesterol lowering beyond currently recommended minimum targets on coronary heart disease (CHD) recurrence in patients with pre-existing CHD. 1998-2004, Pfizer.
18. Pravastatin: Efficacy comparison of different formulations of pravastatin 40 mg. 1998, Bristol-Myers Squibb.
19. Pravastatin: A study to compare the LDL-C lowering efficacy of pravastatin 40 mg administered once daily versus a divided dosing regimen. 1998, Bristol-Myers Squibb.
20. IMPRESS: Inhibition of metalloprotease by BMS-186716 in a randomized exercise and symptoms study in subjects with heart failure. 1998, Bristol-Myers Squibb.
21. Natrecor: Natrecor (nesiritide) versus dobutamine therapy for symptomatic, decompensated CHF: A safety study using 24-hour holter monitoring. 1997, Scios.
22. Natrecor: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Safety and Efficacy of a 24-Hour infusion of NATRECOR hBNP in Subjects with Congestive Heart Failure (BNP). 1995-1996, Scios.
23. Natrecor: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Response Study of the Effects of a 24-Hour Course of NATRECOR hBNP Administered as an Intermittent Intravenous Bolus in Subjects with Congestive Heart Failure on ACE-inhibitor Therapy (BNP). 1995, Scios.
24. Atorvastatin: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, 16-Week, Dose-Ranging Study to Determine the Efficacy of Once Daily Atorvastatin in Patients with Elevated LDL-Cholesterol. 1994, Park-Davis.
25. SWORD (Survival With Oral D-Sotalol): The Effect of Oral d-sotalol on Mortality in Patients with Atherosclerotic Heart Disease and Left Ventricular Dysfunction. 1994, Bristol-Myers Squibb.
26. Pravastatin: A Placebo-Controlled Trial to Evaluate Spermatogenesis during Pravastatin Therapy in Male Subjects with Hypercholesterolemia. 1993-1995, Bristol-Myers Squibb.
27. HEART: Healing and Early Afterload Reducing Therapy. 1993, Hoechst-Roussel.
28. Questran: Comparative evaluation of cholestyramine gel vs. Questran in the treatment of types IIa and IIb hyperlipoproteinemia. 1991, CIBA-Geigy.
29. CARE (Cholesterol and Recurrent Events). A Double-Blind Placebo controlled Secondary Preventive Trial of Lowering Blood Cholesterol after Myocardial Infarction. 1990-1996, Bristol-Myers Squibb.
30. FK506: A randomized trial of FK506 vs. cyclosporine as primary immunosuppressive treatment in liver transplantation: Effects of Lipid, lipoprotein, apoprotein, and glycohemoglobin levels. 1990-1993, Baylor Research Institute.
31. Lopid: A study to compare the efficacy and safety of Lopid modified release formulation to placebo in patients with dyslipidemia. 1989-1991, Parke-Davis.